0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > Integrin alpha V beta 1

Integrin alpha V beta 1

Brief Information

Name:Integrin alpha-V/beta-1
Target Synonym:
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

IT1-H82W6-ELISA
 Integrin alpha V beta 1 ELISA

Immobilized Fibronectin at 5 μg/mL (100 μL/well) can bind Biotinylated Human ITGAV&ITGB1 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT1-H82W6) with a linear range of 0.039-0.625 μg/mL (QC tested).

IT1-H52E1-MALS-HPLC
Integrin alpha V beta 1 MALS images

The purity of Human ITGAV&ITGB1 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT1-H52E1) is more than 85% and the molecular weight of this protein is around 200-245 kDa verified by SEC-MALS.

Synonym Name

Integrin alpha V beta 1,ITGAV&ITGB1

Background

Integrin alpha-5/beta-1 is a receptor for ibrinogen. Integrin alpha-1/beta-1, alpha-2/beta-1, alpha-6/beta-1 and alpha-7/beta-1 are receptors for lamimin. Integrin alpha-4/beta-1 is a receptor for VCAM1. It recognizes the sequence Q-I-D-S in VCAM1. Integrin alpha-9/beta-1 is a receptor for VCAM1, cytotactin and osteopontin. It recognizes the sequence A-E-I-D-G-I-E-L in cytotactin. Integrin alpha-V/beta-1 is also a receptor for vitronectin. Beta-1 integrins recognize the sequence R-G-D in a wide array of ligands. Isoform 2 interferes with isoform 1 resulting in a dominant negative effect on cell adhesion and migration (in vitro). When associated with alpha-7/beta-1 integrin, regulates cell adhesion and laminin matrix deposition.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Bexotegrast PLN-74809 Phase 3 Clinical Pliant Therapeutics Inc Idiopathic Pulmonary Fibrosis; Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Cholangitis, Sclerosing Details
IDL-2965 IDL-2965 Phase 2 Clinical Indalo Therapeutics Inc Metabolic Dysfunction-Associated Steatotic Liver Disease; Idiopathic Pulmonary Fibrosis Details
PLN-1474 PLN-1474 Phase 1 Clinical Pliant Therapeutics Inc, Novartis Pharma Ag Metabolic Dysfunction-Associated Steatotic Liver Disease; Liver Cirrhosis Details
Bexotegrast PLN-74809 Phase 3 Clinical Pliant Therapeutics Inc Idiopathic Pulmonary Fibrosis; Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Cholangitis, Sclerosing Details
IDL-2965 IDL-2965 Phase 2 Clinical Indalo Therapeutics Inc Metabolic Dysfunction-Associated Steatotic Liver Disease; Idiopathic Pulmonary Fibrosis Details
PLN-1474 PLN-1474 Phase 1 Clinical Pliant Therapeutics Inc, Novartis Pharma Ag Metabolic Dysfunction-Associated Steatotic Liver Disease; Liver Cirrhosis Details

This web search service is supported by Google Inc.

totop

Nachricht schicken